Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) from a hold rating to a buy rating in a research report released on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $5.75 price target on the stock.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

NYSEAMERICAN:ARMP opened at $5.76 on Tuesday. The company has a market cap of $156.02 million, a P/E ratio of -5.24 and a beta of 1.17. Armata Pharmaceuticals has a 1-year low of $2.82 and a 1-year high of $10.48.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its quarterly earnings results on Wednesday, November 10th. The company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.04. The business had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $1.02 million. Armata Pharmaceuticals had a negative return on equity of 90.20% and a negative net margin of 594.94%. Analysts predict that Armata Pharmaceuticals will post -1.02 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Armata Pharmaceuticals by 121.4% in the 2nd quarter. Vanguard Group Inc. now owns 167,378 shares of the company’s stock valued at $665,000 after acquiring an additional 91,782 shares in the last quarter. Bridgeway Capital Management LLC raised its holdings in Armata Pharmaceuticals by 134.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 113,400 shares of the company’s stock valued at $450,000 after acquiring an additional 65,000 shares in the last quarter. Synovus Financial Corp raised its holdings in Armata Pharmaceuticals by 108.4% in the 3rd quarter. Synovus Financial Corp now owns 48,060 shares of the company’s stock valued at $174,000 after acquiring an additional 25,000 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Armata Pharmaceuticals by 928.0% in the 3rd quarter. BlackRock Inc. now owns 20,571 shares of the company’s stock valued at $74,000 after purchasing an additional 18,570 shares during the last quarter. 4.40% of the stock is owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Further Reading: Quiet Period Expirations Explained

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.